FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ADAM10-MYO1E

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ADAM10-MYO1E
FusionPDB ID: 1949
FusionGDB2.0 ID: 1949
HgeneTgene
Gene symbol

ADAM10

MYO1E

Gene ID

102

4643

Gene nameADAM metallopeptidase domain 10myosin IE
SynonymsAD10|AD18|CD156c|CDw156|HsT18717|MADM|RAK|kuzFSGS6|HuncM-IC|MYO1C
Cytomap

15q21.3

15q22.2

Type of geneprotein-codingprotein-coding
Descriptiondisintegrin and metalloproteinase domain-containing protein 10a disintegrin and metalloprotease domain 10kuzbanian protein homologmammalian disintegrin-metalloproteaseunconventional myosin-IeMYO1E variant proteinmyosin-ICunconventional myosin 1E
Modification date2020032920200313
UniProtAcc

O14672

Main function of 5'-partner protein: FUNCTION: Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-|-Val-77' to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (PubMed:20592283). Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth-like factor, ephrin-A2, CD44, CDH2 and for constitutive and regulated alpha-secretase cleavage of amyloid precursor protein (APP) (PubMed:26686862, PubMed:11786905, PubMed:29224781). Contributes to the normal cleavage of the cellular prion protein (PubMed:11477090). Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity (PubMed:12475894). Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis (By similarity). Responsible for the FasL ectodomain shedding and for the generation of the remnant ADAM10-processed FasL (FasL APL) transmembrane form (PubMed:17557115). Also cleaves the ectodomain of the integral membrane proteins CORIN and ITM2B (PubMed:19114711, PubMed:21288900). Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3 (By similarity). Mediates the proteolytic cleavage of IL6R and IL11RA, leading to the release of secreted forms of IL6R and IL11RA (PubMed:26876177). Enhances the cleavage of CHL1 by BACE1 (By similarity). Cleaves NRCAM (By similarity). Cleaves TREM2, resulting in shedding of the TREM2 ectodomain (PubMed:24990881). Involved in the development and maturation of glomerular and coronary vasculature (By similarity). During development of the cochlear organ of Corti, promotes pillar cell separation by forming a ternary complex with CADH1 and EPHA4 and cleaving CADH1 at adherens junctions (By similarity). May regulate the EFNA5-EPHA3 signaling (PubMed:16239146). {ECO:0000250|UniProtKB:O35598, ECO:0000269|PubMed:11477090, ECO:0000269|PubMed:11786905, ECO:0000269|PubMed:12475894, ECO:0000269|PubMed:16239146, ECO:0000269|PubMed:17557115, ECO:0000269|PubMed:19114711, ECO:0000269|PubMed:20592283, ECO:0000269|PubMed:21288900, ECO:0000269|PubMed:24990881, ECO:0000269|PubMed:26686862, ECO:0000269|PubMed:26876177, ECO:0000269|PubMed:29224781}.; FUNCTION: (Microbial infection) Promotes the cytotoxic activity of S.aureus hly by binding to the toxin at zonula adherens and promoting formation of toxin pores. {ECO:0000269|PubMed:20624979, ECO:0000269|PubMed:30463011}.

Q12965

Main function of 5'-partner protein: FUNCTION: Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Their highly divergent tails bind to membranous compartments, which are then moved relative to actin filaments. Binds to membranes containing anionic phospholipids via its tail domain. Required for normal morphology of the glomerular basement membrane, normal development of foot processes by kidney podocytes and normal kidney function. In dendritic cells, may control the movement of class II-containing cytoplasmic vesicles along the actin cytoskeleton by connecting them with the actin network via ARL14EP and ARL14. {ECO:0000269|PubMed:11940582, ECO:0000269|PubMed:17257598, ECO:0000269|PubMed:20860408}.
Ensembl transtripts involved in fusion geneENST idsENST00000260408, ENST00000558733, 
ENST00000396140, ENST00000402627, 
ENST00000561288, 
ENST00000558814, 
ENST00000288235, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score14 X 12 X 7=117610 X 11 X 5=550
# samples 1712
** MAII scorelog2(17/1176*10)=-2.79028140869866
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(12/550*10)=-2.1963972128035
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ADAM10 [Title/Abstract] AND MYO1E [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ADAM10 [Title/Abstract] AND MYO1E [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ADAM10(59009776)-MYO1E(59480415), # samples:2
MYO1E(59664697)-ADAM10(59009926), # samples:1
Anticipated loss of major functional domain due to fusion event.ADAM10-MYO1E seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ADAM10-MYO1E seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ADAM10-MYO1E seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ADAM10-MYO1E seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MYO1E-ADAM10 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
MYO1E-ADAM10 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneADAM10

GO:0006509

membrane protein ectodomain proteolysis

12714508|17557115|18355449|18419754|18676862|19114711

HgeneADAM10

GO:0007162

negative regulation of cell adhesion

12714508

HgeneADAM10

GO:0034612

response to tumor necrosis factor

11831872

HgeneADAM10

GO:0051089

constitutive protein ectodomain proteolysis

12714508



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr15:59009776/chr15:59480415)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ADAM10 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across MYO1E (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000260408ADAM10chr1559009776-ENST00000288235MYO1Echr1559480415-46386504442171575
ENST00000260408ADAM10chr1559009775-ENST00000288235MYO1Echr1559480415-46386504442171575

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000260408ENST00000288235ADAM10chr1559009776-MYO1Echr1559480415-0.0004325790.99956745
ENST00000260408ENST00000288235ADAM10chr1559009775-MYO1Echr1559480415-0.0004325790.99956745

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ADAM10-MYO1E

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ADAM10chr1559009775MYO1Echr155948041565068EDQFLRLDFHAHGRVKHQVEYLGLKE
ADAM10chr1559009776MYO1Echr155948041565068EDQFLRLDFHAHGRVKHQVEYLGLKE

Top

Potential FusionNeoAntigen Information of ADAM10-MYO1E in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ADAM10-MYO1E_59009775_59480415.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:05GRVKHQVEY0.99950.78711221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:04GRVKHQVEY0.99940.67531221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B39:06AHGRVKHQV0.99180.66911019
ADAM10-MYO1Echr1559009775chr1559480415650HLA-A74:11RLDFHAHGR0.99090.736514
ADAM10-MYO1Echr1559009775chr1559480415650HLA-A74:09RLDFHAHGR0.99090.736514
ADAM10-MYO1Echr1559009775chr1559480415650HLA-A74:03RLDFHAHGR0.99090.736514
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B38:01AHGRVKHQV0.97920.7811019
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B38:02AHGRVKHQV0.97770.79681019
ADAM10-MYO1Echr1559009775chr1559480415650HLA-A31:06RLDFHAHGR0.97610.7274514
ADAM10-MYO1Echr1559009775chr1559480415650HLA-A31:02RLDFHAHGR0.92210.7021514
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B15:03GRVKHQVEY0.45510.62491221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B15:18GRVKHQVEY0.33840.54091221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:05GRVKHQVEYL0.99970.6691222
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:04GRVKHQVEYL0.99960.62521222
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:04HGRVKHQVEY0.9910.64051121
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:04AHGRVKHQVEY0.99590.62741021
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B15:18AHGRVKHQVEY0.99130.51541021
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:14GRVKHQVEY0.99840.6931221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:03GRVKHQVEY0.99530.81261221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B39:05AHGRVKHQV0.97410.5681019
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C07:27GRVKHQVEY0.96360.88251221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C07:05GRVKHQVEY0.94950.91481221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C07:80GRVKHQVEY0.82260.85361221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C07:67GRVKHQVEY0.82260.85361221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C07:10GRVKHQVEY0.80880.88551221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C07:46GRVKHQVEY0.79180.70131221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C12:16GRVKHQVEY0.07270.87461221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:03GRVKHQVEYL0.99260.72111222
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:03HGRVKHQVEY0.91450.76731121
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C07:46HGRVKHQVEY0.87210.72011121
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:03AHGRVKHQVEY0.91930.67051021
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:08GRVKHQVEY0.99940.6481221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:10GRVKHQVEY0.99930.80381221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-A74:01RLDFHAHGR0.99090.736514
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:06GRVKHQVEY0.98920.66361221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B38:05AHGRVKHQV0.97920.7811019
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:09GRVKHQVEY0.96380.68571221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C07:17GRVKHQVEY0.91920.89351221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C07:02GRVKHQVEY0.82260.85361221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C06:08GRVKHQVEY0.53720.97161221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B48:02GRVKHQVEY0.24510.82651221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B15:53GRVKHQVEY0.21560.71931221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B15:54GRVKHQVEY0.15680.66931221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C06:06GRVKHQVEY0.02140.97611221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C06:17GRVKHQVEY0.0140.96931221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-C06:02GRVKHQVEY0.0140.96931221
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:08GRVKHQVEYL0.99970.51731222
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:10GRVKHQVEYL0.99960.7741222
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:06GRVKHQVEYL0.9990.60111222
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:09GRVKHQVEYL0.99880.58061222
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:08HGRVKHQVEY0.99250.61681121
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:10HGRVKHQVEY0.99190.76161121
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:10AHGRVKHQVEY0.99550.71241021
ADAM10-MYO1Echr1559009775chr1559480415650HLA-B27:08AHGRVKHQVEY0.99530.51891021
ADAM10-MYO1Echr1559009775chr1559480415650HLA-A30:01RLDFHAHGRVK0.97990.9009516

Top

Potential FusionNeoAntigen Information of ADAM10-MYO1E in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ADAM10-MYO1E_59009775_59480415.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-0303DQFLRLDFHAHGRVK116
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1111RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1111LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1111FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1111LDFHAHGRVKHQVEY621
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1114RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1114LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1114FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1120RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1120LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1120FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1145RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1168RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1168LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1168FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1169RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1182RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1182LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1186RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1186LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1186FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1302RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1302LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1302FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1316RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1316LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1316FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1323RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1323LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1323FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1329RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1329LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1329FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1334RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1334LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1334FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1336RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1336LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1336FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1336LDFHAHGRVKHQVEY621
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1338RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1338LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1339RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1339LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1339FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1341RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1341LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1341FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1363RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1363LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1363FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1363LDFHAHGRVKHQVEY621
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1365RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1365LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1367RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1373RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1373LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1373FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1374RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1374LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1374FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1396RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1396LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1396FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1397RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1397LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1397FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1399RLDFHAHGRVKHQVE520
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1399LRLDFHAHGRVKHQV419
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1399FLRLDFHAHGRVKHQ318
ADAM10-MYO1Echr1559009775chr1559480415650DRB1-1424RLDFHAHGRVKHQVE520

Top

Fusion breakpoint peptide structures of ADAM10-MYO1E

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4838LDFHAHGRVKHQVEADAM10MYO1Echr1559009775chr1559480415650

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ADAM10-MYO1E

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN4838LDFHAHGRVKHQVE-7.15543-7.26883
HLA-B14:023BVN4838LDFHAHGRVKHQVE-4.77435-5.80965
HLA-B52:013W394838LDFHAHGRVKHQVE-6.80875-6.92215
HLA-B52:013W394838LDFHAHGRVKHQVE-4.20386-5.23916
HLA-A11:014UQ24838LDFHAHGRVKHQVE-7.5194-8.5547
HLA-A11:014UQ24838LDFHAHGRVKHQVE-6.9601-7.0735
HLA-A24:025HGA4838LDFHAHGRVKHQVE-7.52403-7.63743
HLA-A24:025HGA4838LDFHAHGRVKHQVE-5.82433-6.85963
HLA-B27:056PYJ4838LDFHAHGRVKHQVE-3.28285-4.31815
HLA-B44:053DX84838LDFHAHGRVKHQVE-5.91172-6.94702
HLA-B44:053DX84838LDFHAHGRVKHQVE-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of ADAM10-MYO1E

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ADAM10-MYO1Echr1559009775chr15594804151019AHGRVKHQVCCATGGAAGGGTAAAGCATCAAGTCGA
ADAM10-MYO1Echr1559009775chr15594804151021AHGRVKHQVEYCCATGGAAGGGTAAAGCATCAAGTCGAATATTT
ADAM10-MYO1Echr1559009775chr15594804151121HGRVKHQVEYTGGAAGGGTAAAGCATCAAGTCGAATATTT
ADAM10-MYO1Echr1559009775chr15594804151221GRVKHQVEYAAGGGTAAAGCATCAAGTCGAATATTT
ADAM10-MYO1Echr1559009775chr15594804151222GRVKHQVEYLAAGGGTAAAGCATCAAGTCGAATATTTGGG
ADAM10-MYO1Echr1559009775chr1559480415514RLDFHAHGRTCTAGATTTCCATGCCCATGGAAGGGT
ADAM10-MYO1Echr1559009775chr1559480415516RLDFHAHGRVKTCTAGATTTCCATGCCCATGGAAGGGTAAAGCA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ADAM10-MYO1Echr1559009775chr1559480415116DQFLRLDFHAHGRVKCCAATTTTTACGTCTAGATTTCCATGCCCATGGAAGGGTAAAGCA
ADAM10-MYO1Echr1559009775chr1559480415318FLRLDFHAHGRVKHQTTTACGTCTAGATTTCCATGCCCATGGAAGGGTAAAGCATCAAGT
ADAM10-MYO1Echr1559009775chr1559480415419LRLDFHAHGRVKHQVACGTCTAGATTTCCATGCCCATGGAAGGGTAAAGCATCAAGTCGA
ADAM10-MYO1Echr1559009775chr1559480415520RLDFHAHGRVKHQVETCTAGATTTCCATGCCCATGGAAGGGTAAAGCATCAAGTCGAATA
ADAM10-MYO1Echr1559009775chr1559480415621LDFHAHGRVKHQVEYAGATTTCCATGCCCATGGAAGGGTAAAGCATCAAGTCGAATATTT

Top

Information of the samples that have these potential fusion neoantigens of ADAM10-MYO1E

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
OVADAM10-MYO1Echr1559009775ENST00000260408chr1559480415ENST00000288235TCGA-24-2262

Top

Potential target of CAR-T therapy development for ADAM10-MYO1E

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ADAM10-MYO1E

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ADAM10-MYO1E

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource